三星医疗（601567）2月5日主力资金净买入1560.21万元

Core Viewpoint - Samsung Medical (601567) experienced a decline of 3.78% in stock price, closing at 23.68 yuan on February 5, 2026, with significant net outflows from retail investors and a modest net inflow from institutional investors [1][2]. Financial Performance - For the first three quarters of 2025, Samsung Medical reported a main revenue of 11.08 billion yuan, a year-on-year increase of 6.19%, while the net profit attributable to shareholders was 1.528 billion yuan, a decrease of 15.85% [5]. - The company's gross profit margin stood at 28.46%, with a net profit margin of 13.6% [5]. Market Activity - On February 5, 2026, the stock had a trading volume of 186,900 hands and a total transaction amount of 447 million yuan [1]. - The net inflow of institutional funds was 15.6021 million yuan, accounting for 3.49% of the total transaction amount, while retail investors saw a net outflow of 10.4082 million yuan, representing 2.33% of the total [1][2]. Financing and Margin Trading - On February 5, 2026, the financing balance was 306 million yuan, with a net financing purchase of 1.7974 million yuan [3]. - The margin trading balance stood at 307 million yuan, with a short selling volume of 14,900 shares [3]. Industry Comparison - Samsung Medical's total market capitalization is 33.275 billion yuan, significantly higher than the industry average of 13.548 billion yuan [5]. - The company ranks 6th in the industry with a price-to-earnings ratio of 16.33, compared to the industry average of 146.91 [5].